FDA Clears Shorter Protocol for Nexstim’s Depression Treatment

March 26, 2019

The FDA cleared a shorter treatment protocol for Nexstim’s Navigated Brain Therapy transcranial magnetic stimulator, a system used to treat major depressive disorder.

The device is for adult patients who don’t respond to antidepressant medication. It includes an electronically adjustable chair and positioning holder for the stimulation coil.

The new protocol for the device significantly speeds up the treatment process, taking only three minutes compared to the original 37-minute treatment that was cleared by the FDA in November 2017.

View today's stories